Welcome to the third edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news, including the global regulatory landscape, biosimilars articles and reports and company news as reported via company press releases. The “hot topic” for this edition focuses on the essential role which pharmacovigilance plays in the development of a biosimilar product and in particular the need for strategic planning of post-marketing surveillance activities and the role of observational prospective cohort studies.
Biobetters: Challenges and Opportunities
Please join PRA Health Sciences' Dr. Hazel Gorham as she talks with PharmaVoice about what a biobetter is, how biobetters compare to biosimilars,…
Biosimilars Newsletter Volume 4, October 2014
Welcome to the fourth edition of Biosimilars Newsletter, a quarterly publication dedicated to keeping you updated on current biosimilars news,…